95 related articles for article (PubMed ID: 2078410)
41. Syncytium formation in cultured human lymphoid tissue: fusion of implanted HIV glycoprotein 120/41-expressing cells with native CD4+ cells.
Margolis LB; Glushakova S; Baibakov B; Zimmerberg J
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):697-704. PubMed ID: 7576929
[TBL] [Abstract][Full Text] [Related]
42. Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2.
Steffy KR; Kraus G; Looney DJ; Wong-Staal F
J Virol; 1992 Jul; 66(7):4532-5. PubMed ID: 1602558
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.
Madani N; Hubicki AM; Perdigoto AL; Springer M; Sodroski J
J Virol; 2007 Jan; 81(2):532-8. PubMed ID: 16943294
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons.
Wells DE; Chatterjee S; Mulligan MJ; Compans RW
J Virol; 1991 Nov; 65(11):6325-30. PubMed ID: 1920634
[TBL] [Abstract][Full Text] [Related]
45. Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins.
Salzwedel K; Johnston PB; Roberts SJ; Dubay JW; Hunter E
J Virol; 1993 Sep; 67(9):5279-88. PubMed ID: 8102410
[TBL] [Abstract][Full Text] [Related]
46. Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41.
Arroyo J; Boceta M; González ME; Michel M; Carrasco L
J Virol; 1995 Jul; 69(7):4095-102. PubMed ID: 7769667
[TBL] [Abstract][Full Text] [Related]
47. Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells.
Ashorn PA; Berger EA; Moss B
J Virol; 1990 May; 64(5):2149-56. PubMed ID: 2109100
[TBL] [Abstract][Full Text] [Related]
48. Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.
Mulligan MJ; Yamshchikov GV; Ritter GD; Gao F; Jin MJ; Nail CD; Spies CP; Hahn BH; Compans RW
J Virol; 1992 Jun; 66(6):3971-5. PubMed ID: 1583738
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of HIV-1, HIV-2 and SIV envelope glycoprotein-mediated cell fusion by calmodulin.
Malvoisin E; Wild F
Virus Res; 1997 Aug; 50(2):119-27. PubMed ID: 9282777
[TBL] [Abstract][Full Text] [Related]
50. Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins.
Jernigan KM; Blumenthal R; Puri A
FEBS Lett; 2000 Jun; 474(2-3):246-51. PubMed ID: 10838094
[TBL] [Abstract][Full Text] [Related]
51. Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein.
Dimitrov DS; Blumenthal R
J Virol; 1994 Mar; 68(3):1956-61. PubMed ID: 8107256
[TBL] [Abstract][Full Text] [Related]
52. Inhibitory effect of novel 1-deoxynojirimycin derivatives on HIV-1 replication.
Shimizu H; Tsuchie H; Yoshida K; Morikawa S; Tsuruoka T; Yamamoto H; Ushijima H; Kitamura T
AIDS; 1990 Oct; 4(10):975-9. PubMed ID: 2148090
[TBL] [Abstract][Full Text] [Related]
53. A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines--establishment and validation.
Chiba H; Asanuma S; Okamoto M; Inokoshi J; Tanaka H; Fujita K; Omura S
J Antibiot (Tokyo); 2001 Oct; 54(10):818-26. PubMed ID: 11776437
[TBL] [Abstract][Full Text] [Related]
54. Endocytic entry of HIV-1.
Fackler OT; Peterlin BM
Curr Biol; 2000 Aug; 10(16):1005-8. PubMed ID: 10985390
[TBL] [Abstract][Full Text] [Related]
55. CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycle.
Nara PL; Hwang KM; Rausch DM; Lifson JD; Eiden LE
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7139-43. PubMed ID: 2789382
[TBL] [Abstract][Full Text] [Related]
56. Inhibiting HIV fusion with a beta-peptide foldamer.
Stephens OM; Kim S; Welch BD; Hodsdon ME; Kay MS; Schepartz A
J Am Chem Soc; 2005 Sep; 127(38):13126-7. PubMed ID: 16173723
[TBL] [Abstract][Full Text] [Related]
57. Blocking of HIV-1 infection, but not HIV-1-induced syncytium formation, by a CD4 peptide derivative partly corresponding to an immunoglobulin CDR3.
Ohki K; Kimura T; Ohmura K; Kato S; Ikuta K
AIDS; 1990 Nov; 4(11):1160-1. PubMed ID: 2282193
[No Abstract] [Full Text] [Related]
58. Syncytium formation of human and non-human cells by recombinant vaccinia viruses carrying the HIV env gene and human CD4 gene.
Aoki N; Shioda T; Satoh H; Shibuta H
AIDS; 1991 Jul; 5(7):871-5. PubMed ID: 1909875
[TBL] [Abstract][Full Text] [Related]
59. Temperature enhancement of syncytium formation by HIV and Sendai virus.
Kinchington D; Barker W; Galpin S; Apostolov K
J Med Virol; 1992 Jan; 36(1):44-8. PubMed ID: 1315369
[TBL] [Abstract][Full Text] [Related]
60. Oligopeptides that specifically inhibit membrane fusion by paramyxoviruses: studies on the site of action.
Richardson CD; Choppin PW
Virology; 1983 Dec; 131(2):518-32. PubMed ID: 6689231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
